Registry of patients treated with heavy particle therapy for cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry collects both retrospective and prospective data from patients treated with particle therapy, specifically protons and carbon ions, at the National Center for Oncological Hadrontherapy in Pavia. The aim is to analyze and evaluate clinical outcomes and side effects associated with this advanced form of radiotherapy, which is particularly effective for tumors that are resistant to conventional treatments. By gathering comprehensive data on the natural history of cancer and treatment effects, the registry seeks to enhance understanding of the role of heavy particle therapy in oncology. This initiative will provide valuable insights for future clinical applications and improve patient care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients treated with heavy particles at Fondazione CNAO, Pavia
* Patients who have the ability to understand and be willing to sign a written informed consent document

Exclusion Criteria:

* Patients or legal guardians who are unable to understand informed consent document

Where it's running

• National Center for Oncological Hadrontherapy (CNAO)
  Pavia, Italy Recruiting

Study contacts

• Study coordinator: Chiara Campo, PhD
• Email: campo@cnao.it
• Phone: +39 0382078407

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Skipping the clinical target volume (CTV) around the primary tumor in limited-stage small cell lung cancer

  This trial tests whether giving chest radiotherapy that skips the usual extra margin around the main tumor is as effective and causes fewer side effects for people with limited-stage small cell lung cancer who have responded to initial chemotherapy.

  Recruiting at 2 sites Phase 3 Sun Yat-sen University · Guangzhou, Guangdong and 1 other locations · NCT07008716

• Curative chest re‑irradiation for thoracic cancers

  This project will try a standardized high‑dose re‑radiation approach for adults with recurrent or new thoracic cancers who previously received chest radiotherapy to see how well it controls disease and what toxicities occur.

  Recruiting University of Aarhus · Aarhus, Jutland · NCT06950073

• Next-Gen Fluoroscopy System vs Conventional System in Endoscopy

  This trial tests whether a next-generation fluoroscopy system lowers radiation exposure for patients and staff during fluoroscopy-guided endoscopic procedures.

  Recruiting Orlando Health, Inc. · Orlando, Florida · NCT07594132

• Operator radiation dose during PCI: left distal radial access vs right conventional radial access

  This study tests whether using the left distal radial approach during PCI leads to different radiation exposure for the operator compared with the standard right radial approach in adult patients.

  Recruiting Yonsei University · Osaka and 3 other locations · NCT07579169

• Ozone therapy for refractory pain and quality of life in cancer patients

  This study looks at whether adjuvant ozone therapy can improve quality of life for adults with difficult-to-treat cancer-related symptoms referred to a palliative pain unit.

  Recruiting Hospital Universitario de Gran Canaria Doctor Negrín · Las Palmas de Gran Canaria, Las Palmas · NCT07325851

• Gut microbiome in gynecologic cancer patients with pelvic toxicity

  This study looks at whether gut bacteria profiles relate to pelvic toxicity after cancer treatment and how rectal ozone therapy might affect the gut microbiome and symptoms in women with gynecologic tumors.

  Recruiting at 2 sites Hospital Universitario de Gran Canaria Doctor Negrín · Las Palmas de Gran Canaria, Las Palmas and 1 other locations · NCT07259681

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.